SeraNovo B.V. has signed a second license agreement with Carna Biosciences, Inc., a company developing kinase inhibitors. Under the agreement, the companies will expand their existing collaboration to jointly develop an oral formulation of a new active ingredient with enhanced bioavailability. Using its Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.

Niall Hodgins, Chief Executive Officer of SeraNovo said, “After our initial licence announcement in October 2019, we are pleased to extend our relationship with Carna to include the formulation of another promising active ingredient. This expansion of our partnership with an industry leader is a great development towards wide spread adoption of our breakthrough formulation technology.”